Industry news

• Marrying Empathy & Intentionality in HCP Marketing

  24 September 2021 FiercePharma

  Look, I have been there. I get it. You don’t want to waste your time reading yet another article on the importance of empathy in healthcare marketing. A quick Google search will reveal countless articles where industry leaders weigh in on the importance of infusing patient-centered empathy in all brand communications. Every bulleted list out there tells you that your DTC tactics must include and validate the patient’s daily struggles.

• The unvaccinated are mostly young and non-political, a study finds. Time for pharma to switch up media outreach?

  24 September 2021 Natalie Missakian /FiercePharma

  Counter to vaccine stereotyping, most of the people in the U.S. who shun the COVID-19 shot aren’t political—most don’t vote—and they’re young.

• What’s Driving Record Capital in Genetic Medicine?

  23 September 2021 FiercePharma

  Genetic medicine, the delivery of genetic material as a therapeutic, has attracted record-breaking capital in biotech with ~$150 billion invested across ventures, IPOs, follow-ons and M&A since 2013.

• Remdeform was included in all COVID-19 treatment guidelines

  23 September 2021 GxPnews

  Remdesivir (trade name Remdeform) was included in all inpatient treatment regiments in the 12th version of the temporary guidelines for the treatment of patients with COVID-19 approved by the Ministry of Health of the Russian Federation on September 21, as Pharmasintez, the manufacturer of the drug, reports.

• ARTICLE Six major disruptors for the generics and biosimilars market

  22 September 2021 Hannah Balfour / European Pharmaceutical Review

  In 2020, the global pharmaceutical market was valued at $1.27 trillion, with the generics market accounting for $387.92 billion and the biosimilars market $28.235 billion. Research suggests the global pharmaceutical market could grow to $1.7 trillion in 2025, the global biosimilars market to $21.13 billion that year5 and the global generics market to $650.3 billion, with expansion to continue to $675.29 billion by 2030.

• A warehouse for storing pharmaceutical products to be built in the Moscow region

  22 September 2021 GxPnews

  The Ministry of Housing Policy of the Moscow Region has issued a permit to build a warehouse for storing pharmaceutical products in the Naro-Fominsk municipal district on Chekhov Street. The developer is OOO VITEO. This is reported on the official portal of the Ministry.

• Rare Disease Care: The Benefits of a Specialty Pharmacy

  21 September 2021 FiercePharma

  When a biopharma company develops a therapy for a rare or complex disease, selecting a specialty pharmacy to partner with is an important choice. Choosing one that regularly works with patients who have rare and complex diseases means the specialty pharmacy will be familiar with the challenges a biopharma company faces during the orphan drug commercialization process, whether clinical or logistical.

• The Ministry of Health will conduct studies on the compatibility of vaccines against COVID-19 and influenza

  21 September 2021 GxPnews

  Experts will soon conduct research on the compatibility of vaccines against influenza and coronavirus, as Oleg Gridnev, Deputy Minister of Health of Russia, stated.

• The Ministry of Economic Development proposes to include all patents for medicines into one pharmaceutical register

  20 September 2021 GxPnews

  The Ministry of Economic Development has proposed to create a register of pharmacologically active substances protected by patents for inventions, the Parlamentskaya Gazeta reports. The corresponding draft law was presented by the agency on September 16 at a meeting with foreign companies within the framework of the second meeting of the executive committee of the Advisory Council on Foreign Investment.

• The Ministry of Health proposes to approve risk indicators for the circulation of biomedical cell products

  20 September 2021 GxPnews

  The Ministry of Health of the Russian Federation proposed to approve indicators of the risk of violation of mandatory requirements in the implementation of federal state control (supervision) of biomedical cell products circulation. The draft of the corresponding order is published at regulation.gov.ru.